81 FR 3820 - Notice Pursuant to the National Cooperative Research and Production Act of 1993-Consortium Management Group, Inc. on Behalf of Medical Countermeasure Systems Consortium

DEPARTMENT OF JUSTICE
Antitrust Division

Federal Register Volume 81, Issue 14 (January 22, 2016)

[Federal Register Volume 81, Number 14 (Friday, January 22, 2016)]
[Notices]
[Page 3820]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-01265]



[[Page 3820]]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Consortium Management Group, Inc. on Behalf of 
Medical Countermeasure Systems Consortium

    Notice is hereby given that, on December 8, 2015, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Consortium Management 
Group, Inc. on behalf of Medical Countermeasure Systems Consortium 
(``CMG-MCSC'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing (1) the 
identities of the parties to the venture and (2) the nature and 
objectives of the venture. The notifications were filed for the purpose 
of invoking the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the identities of the parties 
to the venture are: Consortium Management Group, Inc. on behalf of 
Medical Countermeasure Systems Consortium, Washington, DC; ABL, Inc., 
Rockville, MD; Altimmune, Inc., Gaithersburg, MD; AEQUOR, Inc., 
Oceanside, CA; Appili Therapeutics, Inc., Halifax, Nova Scotia; 
BalinBac Therapeutics, Inc., Princeton, NJ; Battelle, Columbus, OH; 
Bavarian Nordic, Kvistgard, DENMARK; Chemapotheca LLC, Delamar, NY; 
CONTINUUS Pharmaceuticals, Inc., Woburn, MA; Creare LLC, Hanover, NH; 
CUBRC, Inc., Buffalo, NY; Dyne Immune Institute for Translational 
Medicine and Research, Wurtsboro, NY; DynPort Vaccine Company LLC, a 
CSC Company, Frederick, MD; Elusys Therapeutics, Inc., Pine Brook, NJ; 
Emergent Biosolutions Inc., Gaithersburg, MD; First Line Technology, 
LLC, Chantilly, VA; GenArraytion, Inc., Rockville, MD; Ginkgo Bioworks, 
Boston, MA; IIT Research Institute, Chicago, IL; Institute for 
Therapeutic Innovation, University of Florida, Orlando, FL; 
InvivoSciences, Inc. Madison, WI; Lovelace Biomedical and Environmental 
Research Institute (LBERI), Albuquerque, NM; Luminex Corporation, 
Austin, TX; Maurer & Hutson Consulting, Seattle, WA; MediVector, Inc., 
Boston, MA; Mesa Science Associates, Inc., Frederick, MD; Molecular 
Engineering & Sciences Institute, Seattle, WA; Murtech, Inc., Glen 
Burnie, MD; Nanotherapeutics, Inc., Alachua, FL; Noninvasix, Inc., 
Galveston, TX; Philips Healthcare, Andover, MA; PnuVax Incorporated, 
Kingston, CANADA; The Preclinical Radiobiology Laboratory, Division of 
Translational Radiation Sciences, Department of Radiation Oncology, 
University of Maryland, School of Medicine, Baltimore, MD; Quintiles, 
Inc., Durham, NC; Science Applications International Corporation, 
McLean, VA; Smart Consulting Group, West Chester, PA; Southern 
Research, Birmingham, AL; Southwest Research Institute, San Antonio, 
TX; Spero Therapeutics, Cambridge, MA; Therabron Therapeutics, Inc., 
Rockville, MD; Trideum Biosciences LLC, Huntsville, AL; University of 
Pittsburgh Center for Military Medicine Research, Pittsburgh, PA; 
Vaxess Technologies, Inc., Cambridge, MA; and Washington to Washington 
Consulting, Seattle, WA.
    The general area of the CMG-MCSC's planned activity is (a) to enter 
into an Other Transaction Agreement (``OTA'') with the U.S. Government 
(``Government'') for the funding of certain research, development, 
testing and evaluation of prototypes to be conducted as a collaboration 
between the Government and Consortium Members, to enhance the 
capabilities of the Government and its departments and agencies in the 
field of countermeasures against chemical, biological, radiological and 
nuclear threats; (b) to develop countermeasures, first response and 
resilient systems; (c) to participate in the establishment of sound 
technical and programmatic performance goals based on the needs and 
requirements of the Government's Technology Objectives; (d) to provide 
a unified voice to effectively articulate the global and strategically 
important role medical countermeasures play in current and future 
national security objectives; and (e) to maximize the utilization of 
the Government's and Members' capabilities to effectively develop 
critical technologies which can be deployed and transitioned.

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2016-01265 Filed 1-21-16; 8:45 am]
 BILLING CODE P